Summary.
Patients with Parkinson's disease (n = 68) switched from per-golide or bromocriptine to ropinirole overnight (dose equivalence ratios – 1 : 6 and 10 : 6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine–ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received January 28, 1999; accepted June 30, 1999
Rights and permissions
About this article
Cite this article
Canesi, M., Antonini, A., Mariani, C. et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. J Neural Transm 106, 925–929 (1999). https://doi.org/10.1007/s007020050212
Issue Date:
DOI: https://doi.org/10.1007/s007020050212